β¨ Medicines Distribution Consents
2596 NEW ZEALAND GAZETTE, No. 98 12 JUNE 2008
Schedule
Product:
Tarceva
Active Ingredient:
Erlotinib hydrochloride 109.29mg equivalent to erlotinib 100mg
Dosage Form:
Tablet Film coated
New Zealand Sponsor:
Roche Products (New Zealand) Limited
Manufacturers:
F Hoffmann-La Roche Limited, Basel, Switzerland
Schwarz Pharma Manufacturing Inc, Seymour, Indiana, United States of America
Product:
Tarceva
Active Ingredient:
Erlotinib hydrochloride 163.93mg equivalent to erlotinib 150mg
Dosage Form:
Tablet Film coated
New Zealand Sponsor:
Roche Products (New Zealand) Limited
Manufacturers:
F Hoffmann-La Roche Limited, Basel, Switzerland
Schwarz Pharma Manufacturing Inc, Seymour, Indiana, United States of America
Product:
Tarceva
Active Ingredient:
Erlotinib hydrochloride 27.32mg equivalent to erlotinib 25mg
Dosage Form:
Tablet Film coated
New Zealand Sponsor:
Roche Products (New Zealand) Limited
Manufacturers:
F Hoffmann-La Roche Limited, Basel, Switzerland
Schwarz Pharma Manufacturing Inc, Seymour, Indiana, United States of America
Dated this 3rd day of June 2008.
JOHN HAZELDINE, Acting Deputy Director-General, Sector Accountability and Funding Directorate (pursuant to delegation
given by the Minister of Health on 6 July 2001).
go4121
Provisional Consent to the Distribution of a Medicine
Pursuant to section 23(1) of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply
or use in New Zealand of the medicine set out in the Schedule hereto:
Schedule
Product:
Potassium 10mmol
Active Ingredient:
Potassium chloride 7.385g/L
Dosage Form:
Solution for infusion
New Zealand Sponsor:
Baxter Healthcare Limited
Manufacturer:
Baxter Healthcare Pty Limited, Old Toongabbie, New South Wales, Australia
Note: This consent is valid for two years from the date of publication of this notice.
Product:
Potassium 40mmol
Active Ingredient:
Potassium chloride 2.95g/L
Dosage Form:
Solution for infusion
New Zealand Sponsor:
Baxter Healthcare Limited
Manufacturer:
Baxter Healthcare Pty Limited, Old Toongabbie, New South Wales, Australia
Note: This consent is valid for two years from the date of publication of this notice.
Dated this 3rd day of June 2008.
JOHN HAZELDINE, Acting Deputy Director-General, Sector Accountability and Funding Directorate (pursuant to delegation
given by the Minister of Health on 6 July 2001).
go4122
Consent to the Distribution of New Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of
the new medicines set out in the Schedule hereto:
Schedule
Product:
Alendrate
Active Ingredient:
Alendronate sodium trihydrate 13.05mg equivalent to 10mg alendronic acid
Dosage Form:
Tablet
New Zealand Sponsor:
Pacific Pharmaceuticals Limited (part of Mylan)
Manufacturer:
McDermott Laboratories, t/a Gerard Laboratories, Dublin, Ireland
Next Page →
Online Sources for this page:
VUW Te Waharoa —
NZ Gazette 2008, No 98
Gazette.govt.nz —
NZ Gazette 2008, No 98
β¨ LLM interpretation of page content
π₯
Consent to the Distribution of a Changed Medicine
(continued from previous page)
π₯ Health & Social Welfare3 June 2008
Medicines Act, Changed Medicine, Distribution Consent, Tarceva
- JOHN HAZELDINE, Acting Deputy Director-General, Sector Accountability and Funding Directorate
π₯ Provisional Consent to the Distribution of a Medicine
π₯ Health & Social Welfare3 June 2008
Medicines Act, Provisional Consent, Potassium, Baxter Healthcare
- JOHN HAZELDINE, Acting Deputy Director-General, Sector Accountability and Funding Directorate
π₯ Consent to the Distribution of New Medicines
π₯ Health & Social Welfare3 June 2008
Medicines Act, New Medicine, Alendrate, Pacific Pharmaceuticals
- JOHN HAZELDINE, Acting Deputy Director-General, Sector Accountability and Funding Directorate